Company: JUNS
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001493152-25-023603
Chunk: 144

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-11-14
Form: 10-Q
Item: Item 1
Chunk 144
---
significantly improved bioavailability. The Company’s prescription pipeline is focused broadly on CNS disorders, presently with
a planned Phase IIa clinical study in Parkinson’s disease. The Company’s Nugevia product line brings clinical-grade science
to the supplement space, supporting mental clarity, skin health, and mitochondrial function.

The
Company completed preclinical studies at the University of Miami for Parkinson’s Disease in 2021. These studies used a validated
mouse model to mimic human disease characteristics. The promising results have led the Company to plan a Phase IIa clinical trial for
Parkinson’s Disease, which is expected to start in the fourth quarter of 2025, with results anticipated 12 months later. The Company
also aims to explore other CNS indications, such as Mild Cognitive Impairment (“MCI”) and Alzheimer’s disease, following
the Parkinson’s study

The
Company believes, based on pre-clinical and clinical studies, that high doses of resveratrol are necessary for therapeutic effects. Current
resveratrol products cannot reach these levels without causing severe gastrointestinal side effects. Indications are from human studies
in Alzheimer’s patients (Turner et al 2015) and Friedreich’s Ataxia patients (Yu et al 2015) that a concentration at the
highest dose (CMax) of resveratrol in blood plasma needs to be 200 ng/ml or higher for therapeutic effect. A Phase 1 study with
500mg of resveratrol as a maximum dose in the JOTROL formulation showed levels of resveratrol exceeding 800 ng/ml without generating
any severe adverse events (AAPS Open 2022). Resveratrol was shown in the Turner Alzheimer’s study to cross the blood-brain
barrier, indicating positive effects on oxidative stress and inflammation. Subsequent analysis published in Molecular Science 2025 (Mousa
et al) further indicates that resveratrol has effect on neurodegeneration and neuroinflammation in Alzheimer’s patients.

Over
the past two years, JOTROL has garnered significant interest from Asian organizations. This interest is partly due to resveratrol’s
use in Asian herbal medicines, recent patent approvals in Hong Kong and China, and China’s list of rare disease indications where
JOTROL could be applicable. Additionally, recent publications in the Journal of Alzheimer’s Disease and AAPS Open, along with the
projected growth of the Traditional Chinese Medicine market, have contributed